Use of continuous glucose monitoring (CGM) allows a more complete assessment of overall glycaemic control and supports time-in-range (time a patient is within the glycaemic range of 70 to 180 mg/dL) as a treatment target.

At present, there is no CGM literature on the use of CGM to compare the second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100).

InRange, a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4 study will collect CGM data over 20 consecutive days from adults with T1D randomised to receive Gla-300 or IDeg-100.

The study is designed to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time in range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)] and coefficient of variation, as assessed using CGM, in adults with T1D.

InRange is expected to provide further insight into the utility of CGM as an outcome measure in clinical practice.